2.60
+0(+0.00%)
Currency In USD
| Previous Close | 2.6 |
| Open | 2.61 |
| Day High | 2.67 |
| Day Low | 2.53 |
| 52-Week High | 36 |
| 52-Week Low | 2.33 |
| Volume | 30,780 |
| Average Volume | 168,258 |
| Market Cap | 7.05M |
| PE | -0.1 |
| EPS | -24.88 |
| Moving Average 50 Days | 4.72 |
| Moving Average 200 Days | 11.2 |
| Change | 0 |
If you invested $1000 in AIM ImmunoTech Inc. (AIM) 10 years ago, it would be worth $27.36 as of September 13, 2025 at a share price of $2.6. Whereas If you bought $1000 worth of AIM ImmunoTech Inc. (AIM) shares 5 years ago, it would be worth $1,354.17 as of September 13, 2025 at a share price of $2.6.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland
GlobeNewswire Inc.
Sep 04, 2025 3:00 PM GMT
AIM CEO Thomas K. Equels AIM CEO Thomas K. Equels Latest progress from lead program Ampligen for the treatment of pancreatic cancer highlighted at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSC
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
GlobeNewswire Inc.
Aug 21, 2025 1:00 PM GMT
Tom Equels, CEO of AIM ImmunoTech provides a corporate update and reiterates focus on driving Ampligen forward in pancreatic cancerOCALA, Fla., Aug. 21, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), tod
AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
Aug 15, 2025 1:00 PM GMT
Continued progress across pipeline programs with focus on pancreatic cancer Mid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca’s Imfinzi® (durvalumab) for the treatment of pancreatic cancer demonstrates promising signs of bot